Ouro Medicines Acquired by Gilead Sciences | Healthcare M&A Deal

Gilead Sciences has completed the acquisition of Ouro Medicines, a substance abuse treatment business in the inflammation pipeline in the healthcare sector. Gilead Sciences acquires Ouro Medicines to broaden its inflammation-focused drug development efforts and strengthen its therapeutic pipeline. Ouro Medicines supports research and development activities relevant to inflammation and related indications, aligning with Gilead Sciences acquisitions strategy. The strategic acquisition was executed as a healthcare M&A transaction with Lakefront as the co-acquirer, and the deal status is closed; deal value was not disclosed.